StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) company profile

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30240% above fair value
$144.46−3.30 (-2.23%)

Close on Nov 16, 2026Market cap $356.41BP/E 115.6Yield 2.27%

About Merck

Pharmaceutical Preparations, SIC 2834

Merck & Co., Inc. is a global healthcare company that provides prescription medicines, biologic therapies, vaccines, and animal health solutions. Its business is managed across two operating segments: Pharmaceutical and Animal Health. The Pharmaceutical division supplies human therapeutics and vaccines across oncology, hospital acute care, cardiometabolic conditions, virology, and diabetes to drug wholesalers, retailers, hospitals, government agencies, and physicians. The Animal Health segment delivers veterinary medications, vaccines, and digital identification and monitoring technologies for livestock and companion animals to veterinarians, distributors, farmers, and pet owners.

Merck operates globally with commercial presence and regulatory approvals across multiple regions, including the United States, Europe, China, and Japan. The company partners with international research and commercialization allies to develop and distribute products across worldwide markets. The provided text does not state the company's headquarters location or a specific count of operating facilities or countries.

Summary of the business section of Merck's latest annual report, written by StockData.

Company profile

Company

Legal name
Merck & Co., Inc.
Founded
1891
Headquarters
Rahway, NJ
Address
126 East Lincoln Avenue, P.O. Box 2000 07065
Phone
(908) 740-4000
Website
www.msd.no
Employees
75,000, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
New Jersey
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Florham Park, New Jersey

Stock & identifiers

Ticker
MRK
Exchange
NYSE
Shares outstanding
2.47B, Jul 31, 2026
Public float
$198.05B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
2-for-1, Feb 17, 1999; 3-for-1, May 26, 1992; 3-for-1, May 26, 1988; 2-for-1, May 27, 1986; 2-for-1, Jun 1, 1972; 3-for-1, May 27, 1964
SEC CIK
310158
CUSIP
58933Y105
ISIN
US58933Y1055
FIGI
BBG000BPD168
Share class FIGI
BBG001S5TC52
LEI
4YV9Y5M8S0BRK1RP0397
EIN
22-1918501

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Robert M. DavisChairman, CEO & President, Director450,351
Richard R. DeLucaEVP&Pres, Merck Animal Heallth114,291
David R. MaraldoEVP & Pres. MMD23,769
Gaurav K. GuptaEVP, CIDO750
Chirfi GuindoEVP, Access, Policy & Comms36,670
Jennifer ZacharyEVP, General Counsel125,824
David Michael WilliamsEVP,Chief Info&Digital Officer31,716
Dalton E. Smart IIISVP Fin. - Global Controller9,388
Betty D. LarsonEVP, Chief HR Officer13,774
Johannes Jacobus OosthuizenEVP, Oncology & Int?l21,895
Brian FoardEVP, Specialty, Pharma, & ID–
Caroline LitchfieldEVP & CFO92,301
Dean Y. LiExecutive VP & President, MRL94,431
Sanat ChattopadhyayExe V-P & Pres. MMD200,675
Joseph RomanelliPresident, Human Health Int?l28,739
Cristal N. DowningChief Comm. & Public Afrs Ofcr0
Paul J. DiazDirector296
Christine E. SeidmanDirector100
Mary Ellen CoeDirector10
Surendralal Lanca KarsanbhaiDirector1
Paul RothmanDirector100
Risa J. Lavizzo-MoureyDirector1,000
Stephen MayoDirector100
Patricia F. RussoDirector13,148
Douglas M. Baker JrDirector16,000

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$20.80M$15.76M$6.92M$158$198
FY2024$23.19M$14.73M$9.49M$144$146
FY2023$20.27M$26.70M$7.63M$154$134
FY2022$18.65M$52.47M$8.41M$152$130
FY2021
Mr.Davis
$13.72M$14.39M$6.71M$102$122
FY2021
Mr.Frazier
$15.20M$13.33M$6.71M$102$122

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Robert M. Davis
Chairman, Chief Executive Officer and President
$1.65M$12.10M$3.38M$2.33M$1.34M$20.80M-10%
Caroline Litchfield
Executive Vice President and Chief Financial Officer
$1.17M$3.58M$1.00M$1.10M$660.38K$7.51M+0%
Sanat Chattopadhyay
Executive Vice President and President, Merck Manufacturing Division
$982.17K$2.36M$660.00K$920.71K$482.26K$5.41M-12%
Dean Li, M.D., Ph.D.
Executive Vice President and President, Merck Research Laboratories
$1.46M$4.30M$1.20M$1.37M$567.39K$8.89M-12%
Jennifer Zachary
Executive Vice President and General Counsel
$1.06M$2.69M$750.00K$995.75K$367.04K$5.86M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, the Company had approximately 75,000 employees worldwide, including approximately 30,000 people in the U.S., including Puerto Rico, and approximately 15,000 third-party contractors globally.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 15, 2026DelistingNotice of delisting from exchange (Form 25)
Apr 7, 2026Tender offerThird-party tender offer for the company's shares
Dec 5, 2025Tender offerThird-party tender offer for the company's shares
Nov 4, 2024DelistingNotice of delisting from exchange (Form 25)
May 30, 2024ListingRegistration of securities on an exchange (Form 8-A)
Oct 15, 2021DelistingNotice of delisting from exchange (Form 25)
Jun 3, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 17, 2019Tender offerThird-party tender offer for the company's shares
Mar 5, 2019Tender offerThird-party tender offer for the company's shares
Nov 2, 2016ListingRegistration of securities on an exchange (Form 8-A)
Dec 19, 2014Tender offerThird-party tender offer for the company's shares
Oct 15, 2014ListingRegistration of securities on an exchange (Form 8-A)
Oct 2, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 20, 2014Tender offerThird-party tender offer for the company's shares
Aug 13, 2010DelistingNotice of delisting from exchange (Form 25)
Nov 4, 2009Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 4, 2009Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 29, 2009Name changeName changed from SCHERING PLOUGH CORP to Merck & Co. Inc.
May 20, 2009MergerRegistration of securities for a merger or exchange offer (S-4)
Nov 26, 2007Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 19, 2007DelistingNotice of delisting from exchange (Form 25)
Aug 9, 2007ListingRegistration of securities on an exchange (Form 8-A)
Aug 6, 2004ListingRegistration of securities on an exchange (Form 8-A)
Jun 30, 1997ListingRegistration of securities on an exchange (Form 8-A)
Dec 18, 1995MergerRegistration of securities for a merger or exchange offer (S-4)

See a number that looks wrong?